Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority.
Amubarvimab and romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal …

Background Remdesivir is considered to be a specific drug for treating coronavirus disease
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Objectives The potential benefit of convalescent plasma (CP) therapy for coronavirus
disease 2019 (COVID-19) is highest when administered early after symptom onset. Our …

Convergence of the two pandemics: metabolic syndrome and COVID-19 over last two years
has posed unprecedented challenges to individuals as well as healthcare systems …

The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable
clinical severity and ability to escape preexisting immunity emphasizes the continued need …

Patients with multiple myeloma (MM) have a lower efficacy from COVID‐19 vaccination and
a high rate of mortality from COVID‐19 in hospitalized patients. However, the overall rate …

Despite unprecedented efforts, our therapeutic arsenal against SARS-CoV-2 remains
limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP …

Introduction There are currently some differences in the research results of molnupiravir.
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …